You are here: Industry Insights > Merck

News List

Keytruda has a blockbuster market not factored into Merck’s forecasts—China fiercepharma
March 18, 2019
Merck & Co.’s Keytruda is already the best-selling immuno-oncology drug on the market, but as one group of analysts sees it, the drug still has one key upside opportunity that’s not yet calculated into forecasts: the Chinese market.
Merck limits orders for bladder cancer drug as demand outstrips supply fiercepharma
March 15, 2019
When Sanofi said it’d stop making a bladder cancer drug in 2016, one expert predicted there’d be shortages. Fast forward to today, and Merck says it’s done it’s best to ensure global supply, but as the lone manufacturer, it’s having trouble keeping up.
Merck to use Generative Modelling AI technology biospectrumasia
March 15, 2019
Generative modelling AI technology enables rapid and cost-effective design of novel drugs
Louisiana's 'Netflix' deal for hepatitis C drugs wins bids from AbbVie, Gilead and Merck fiercepharma
March 08, 2019
States across the U.S. have taken on high drug prices with new laws, proposals and Medicaid rules, many of them unpopular with the pharma industry.
Merck receives Canadian CRISPR Nickase Patent biospectrumasia
March 05, 2019
Patent covers paired Cas9 nickase technology to advance gene therapy and research, reduce off-target effects
EMA panel backs approval of AstraZeneca, Merck & Co.'s PARP inhibitor Lynparza in breast cancer firstwordpharma
March 04, 2019
AstraZeneca and partner Merck & Co. on Friday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of the PARP inhibitor Lynparza (olaparib) as monotherapy for the treatment of HER2-nega
Merck agrees to acquire Immune Design for $300m pharmaceutical-technology
February 26, 2019
Merck has reached an agreement to acquire all outstanding shares of US-based late-stage immunotherapy firm Immune Design in an all cash deal valued at approximately $300m, or $5.85 per share....
Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb's kidney cancer share fiercepharma
February 24, 2019
Bristol-Myers Squibb investors have been dreading positive kidney cancer results from archrival Merck for months. And now that they’re here, they might do even more damage to Bristol-Myers’ market share than some industry watchers expected.
Merck's Keytruda hits the skids in pivotal trial, putting its liver cancer nod at risk fiercepharma
February 24, 2019
Merck & Co.’s immunotherapy Keytruda has been hitting its trial targets so often, it’s tempting to think it can't miss. But it can—and Tuesday’s data in liver cancer proves it.
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets fiercepharma
February 24, 2019
This year is already shaping up to be a big one for biopharma mergers and acquisitions, with Bristol-Myers Squibb’s planned $74 billion buyout of Celgene well underway. But analysts at Morningstar are predicting the BMS-Celgene deal will mark the beginnin

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page